In this episode (19:37), Medicom’s correspondent covers 6 presentations from the annual meeting of the European Society of Medical Oncology 2023, 20–24 October, held in Madrid, Spain.
The topics discussed are:
- Durvalumab climbs the MATTERHORN of gastric cancer
The addition of PD-L1 inhibitor durvalumab to chemotherapy shows positive findings for pathological complete response (pCR) rate when given in the perioperative setting for patients with untreated, resectable gastric/gastro-oesophageal junction (GC/GEJ) cancers, results from MATTERHORN show. The impact on survival is still uncertain. - Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
Last year, NICHE-2 showed impressive pathological response rates of neoadjuvant nivolumab/ipilimumab in patients with mismatch repair deficient (dMMR) colon cancer, Now, NICHE-3 shows equally impressive pathological response rates after nivolumab/relatlimab neoadjuvant treatment of dMMR colon cancer. - Benefit of pembrolizumab in TNBC remains after 5 years follow-up
The addition of pembrolizumab to both neoadjuvant and adjuvant chemotherapy improves event-free survival in patients with early triple-negative breast cancer (TNBC), as updated results of KEYNOTE-522 show. - Two potential new first-line standards of care in metastatic urothelial cancer
First-line treatment with enfortumab vedotin (EV) combined with pembrolizumab significantly improved progression-free (PFS) and overall survival (OS) in patients with locally advanced or metastatic urothelial cancer, as was shown by the results of the EV-302/KEYNOTE-A39 trial. - Short-induction chemotherapy improves survival in advanced cervical cancer
The addition of 6 cycles of carboplatin/paclitaxel induction chemotherapy, directly followed by standard chemoradiotherapy improved progression-free and overall survival in participants with locally advanced cervical cancer by almost 40%, results of phase 3 INTERLACE trial show. - Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
Patients with KRASG12C-mutated, metastatic colorectal cancer (CRC) benefit from treatment with the combination of sotorasib, a KRASG12C mutation-selective inhibitor, and the EGFR-inhibitor panitumumab, first results from the phase 3 CodeBreak 300 trial show. Overall survival data is not yet mature.
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Reprogramming stem cells to heal intestinal mucosa in IBD: fact or fiction? Next Article
Championing the cause against pancreatic cancer – Interview with Ali Stunt »
« Reprogramming stem cells to heal intestinal mucosa in IBD: fact or fiction? Next Article
Championing the cause against pancreatic cancer – Interview with Ali Stunt »
Table of Contents: ESMO 2023
Featured articles
The importance of detecting early NSCLC
Breast Cancer
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy
Colorectal Cancer
Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
Postoperative ctDNA predicts survival in colorectal cancer
Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen
Lung Cancer
Perioperative nivolumab boosts event-free survival in NSCLC
Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC
Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC
First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC
Upper Gastro-Intestinal Cancer
Perioperative durvalumab/FLOT improves pCR in gastric cancer
Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
Melanoma
Lifileucel induces a durable response in heavily pretreated mucosal melanoma
Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma
Genito-Urinary Cancers
Two potential new first-line standards of care in metastatic urothelial cancer
LuPSMA and enzalutamide: a promising combination
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy
Gynaecological Cancers
Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer
Short-induction chemotherapy improves survival in advanced cervical cancer
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer
Featured Interviews
Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?
The importance of detecting early NSCLC
Related Articles
August 23, 2022
Interventions needed to address sexual health in lung cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com